Research Article

Prognostic Impact of Prephase Treatment Prior to First-Line Treatment in DLBCL: A Population-Based Registry Study

Table 2

Grade III-IV toxicities after the first-line regimens of diffuse large B-cell lymphoma.

All patients (N = 340)Before propensity score matchingAfter propensity score matching
With prephase (N = 126)Without prephase (N = 214)With prephase (N = 97)Without prephase (N = 97)

All toxicities92 (27%)40 (32%)52 (24%)0.1425 (26%)27 (28%)0.75
 Febrile neutropenia23 (7%)15 (12%)8 (4%)0.0049 (9%)5 (5%)0.27
 Neutropenia74 (22%)34 (27%)40 (19%)0.0722 (23%)20 (21%)0.73
 Anemia13 (4%)8 (6%)5 (2%)0.081 (1%)1 (1%)1.00
 Thrombocytopenia10 (3%)5 (4%)5 (2%)0.514 (4%)2 (2%)0.68
 Infection28 (8%)19 (15%)9 (4%)0.000411 (11%)6 (6%)0.20
 Cardiac toxicity4 (1%)2 (2%)2 (1%)0.632 (2%)2 (2%)1.00
 Neurologic toxicity2 (1%)1 (1%)1 (1%)1.001 (1%)01.00